AQST Financials | Key Metrics & Investor Analysis

The financial statements for AQST (AQST) provide a snapshot of revenue trends, balance-sheet strength, and cash flow quality. Reviewing these together helps investors evaluate earnings durability, capital structure, and whether operating cash flow supports long-term business growth.

See stock fair value and complete historical financials—premium unlocks deeper tables and metrics.

Financial Statements

Related peers

Compare More →
EBS
Emergent BioSolutions Inc.
$8.66
+0.00%
MLTX
MoonLake Immunotherapeutics
$18.02
-4.05%
ERAS
Erasca, Inc.
$18.20
+1.96%
SNDL
SNDL Inc.
$1.53
+6.25%
SIGA
SIGA Technologies, Inc.
$4.70
+2.62%
ESPR
Esperion Therapeutics, Inc.
$2.17
+5.85%

Frequently Asked Questions

What are AQST's latest financial results?

Review AQST's latest balance sheet, income statement, and cash flow to understand its profitability, revenue trends, and financial health. These metrics are essential for evaluating short-term performance and long-term stability.

How has AQST's revenue and net income changed over time?

Analyzing historical revenue and net income shows growth trends and business performance. Consistent growth indicates operational strength, while declines may signal challenges that investors should consider.

What is AQST's cash flow situation and liquidity?

Cash flow statements reveal how AQST generates and uses cash. Strong operating cash flow and sufficient liquidity suggest the company can fund operations, pay dividends, and handle debt effectively.

How does AQST's financial performance compare to industry peers?

Comparing key metrics like revenue growth, profit margins, and debt levels with competitors helps investors assess whether AQST is outperforming or lagging within its sector.

Are AQST's financial statements showing sustainable profitability?

By analyzing margins, ROE, ROIC, and cash generation over multiple periods, investors can evaluate whether AQST's profits are repeatable and supported by strong fundamentals.